Authors: Kouya Yamaki Takayuki Nakashima Kenji Miyatake Yuki Ishibashi Ayaka Ito Ayu Kuranishi Akihito Taguchi Ayumi Morioka Midori Yamamoto Shin Yoshino
Publish Date: 2013/12/24
Volume: 58, Issue: 1, Pages: 106-117
Abstract
Administration of the influenza vaccination to patients with an egg allergy is major health concern Contaminating egg antigens occasionally induce severe anaphylactic shock in these patients following administration of the vaccination therefore the development of a safer vaccination is needed In the present study we investigated whether a mixture of four newly and previously generated antiovalbumin OVA IgA monoclonal antibodies mAbs could inhibit both anaphylactic shock upon a subcutaneous OVA challenge and subsequent further sensitization against OVA in passively antiOVA IgEsensitized mice and actively sensitized mice with an injection of OVA The prevention of anaphylaxis by antiOVA IgA mAbs was suggested to be mediated through the inhibition of OVA binding to allergenic antibodies such as antiOVA IgE on mast cells and deceleration of the rate of OVA penetration from the injected site into the systemic circulation AntiOVA IgA mAbs inhibited further sensitization against OVA in mice actively sensitized with OVA but did not affect sensitization against the unrelated antigen phosphorylcholinekeyhole limpet hemocyanin coinjected with OVA Our findings indicate that adding the antiegg antigen IgA to the influenza vaccine should reduce not only the risk of inducing anaphylactic shock but also undesired further sensitization against egg antigens following the vaccination without affecting the intended beneficial effect of the vaccine namely the upregulation of immune responses to influenza viruses
Keywords: